Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468414 · ClinicalTrials.gov registry record · Phase 2
TARGTEPO Treatment for Anemia in PD US Trial
A Phase 2 study, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02468414 is a Phase 2 study that was terminated before completion, run by Aevi Genomic Medicine, LLC, a Cerecor company. The registered enrollment target is 3 participants.
The verdict
NCT02468414, a Phase 2 study, was terminated before completion, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
Interventions
- BIOLOGICAL MDGN201 TARGTEPO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02468414
The ClinicalTrials.gov registry entry for NCT02468414 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDGN201 TARGTEPO is the first listed.
NCT02468414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02468414 about?
NCT02468414 is a clinical study titled "TARGTEPO Treatment for Anemia in PD US Trial". The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
What is the current status of trial NCT02468414?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2015-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02468414?
The interventions under investigation include: MDGN201 TARGTEPO (BIOLOGICAL).
Who is sponsoring clinical trial NCT02468414?
This trial is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.